https://www.biospace.com/kidney-disease Kidney disease en-US Tue, 22 Sep 2026 13:56:18 GMT https://www.biospace.com/press-releases/vertex-announces-positive-results-from-phase-2b-amplified-study-of-inaxaplin-in-additional-populations-of-people-with-apol1-mediated-kidney-disease-amkd-and-completion-of-enrollment-in-the-phase-2-3-amplitude-trial Tue, 22 Sep 2026 13:56:18 GMT https://www.biospace.com/press-releases/vertex-announces-positive-results-from-phase-2b-amplified-study-of-inaxaplin-in-additional-populations-of-people-with-apol1-mediated-kidney-disease-amkd-and-completion-of-enrollment-in-the-phase-2-3-amplitude-trial https://www.biospace.com/press-releases/aclipse-therapeutics-and-cypress-biopharma-announce-agreement-to-launch-phase-2-study-in-childhood-nephrotic-syndrome-and-expand-renal-development-capabilities Tue, 22 Sep 2026 13:54:01 GMT https://www.biospace.com/press-releases/aclipse-therapeutics-and-cypress-biopharma-announce-agreement-to-launch-phase-2-study-in-childhood-nephrotic-syndrome-and-expand-renal-development-capabilities https://www.biospace.com/press-releases/bayers-kerendia-finerenone-receives-fda-approval-as-the-first-new-treatment-in-30-years-for-adults-with-chronic-kidney-disease-ckd-and-type-1-diabetes Thu, 17 Sep 2026 09:36:07 GMT https://www.biospace.com/press-releases/bayers-kerendia-finerenone-receives-fda-approval-as-the-first-new-treatment-in-30-years-for-adults-with-chronic-kidney-disease-ckd-and-type-1-diabetes https://www.biospace.com/press-releases/walden-biosciences-announces-cmo-appointment-and-upcoming-clinical-data-for-wal0921-in-proteinuric-chronic-kidney-disease Tue, 15 Sep 2026 11:18:17 GMT https://www.biospace.com/press-releases/walden-biosciences-announces-cmo-appointment-and-upcoming-clinical-data-for-wal0921-in-proteinuric-chronic-kidney-disease https://www.biospace.com/press-releases/vera-therapeutics-announces-trutakna-atacicept-vymj-stabilized-egfr-and-prevented-kidney-disease-progression-through-two-years-in-origin-3-final-efficacy-analysis-in-iga-nephropathy Tue, 15 Sep 2026 11:17:34 GMT https://www.biospace.com/press-releases/vera-therapeutics-announces-trutakna-atacicept-vymj-stabilized-egfr-and-prevented-kidney-disease-progression-through-two-years-in-origin-3-final-efficacy-analysis-in-iga-nephropathy https://www.biospace.com/press-releases/one04-therapeutics-launches-on-encouraging-cpv-104-phase-1-interim-results-and-plans-to-expand-clinical-development-to-include-kidney-diseases-and-dry-amd Tue, 15 Sep 2026 10:30:01 GMT https://www.biospace.com/press-releases/one04-therapeutics-launches-on-encouraging-cpv-104-phase-1-interim-results-and-plans-to-expand-clinical-development-to-include-kidney-diseases-and-dry-amd https://www.biospace.com/press-releases/akebia-therapeutics-announces-first-patient-dosed-in-phase-2-basket-trial-of-ebribafusp-in-rare-complement-mediated-kidney-diseases Mon, 14 Sep 2026 13:29:00 GMT https://www.biospace.com/press-releases/akebia-therapeutics-announces-first-patient-dosed-in-phase-2-basket-trial-of-ebribafusp-in-rare-complement-mediated-kidney-diseases https://www.biospace.com/press-releases/vincere-biosciences-awarded-2-7-million-nih-grant-to-advance-usp30-inhibitor-for-acute-kidney-injury Thu, 10 Sep 2026 13:15:22 GMT https://www.biospace.com/press-releases/vincere-biosciences-awarded-2-7-million-nih-grant-to-advance-usp30-inhibitor-for-acute-kidney-injury https://www.biospace.com/press-releases/dimerix-secures-a-34-million-non-dilutive-facility-to-fund-key-clinical-milestones Fri, 04 Sep 2026 12:18:44 GMT https://www.biospace.com/press-releases/dimerix-secures-a-34-million-non-dilutive-facility-to-fund-key-clinical-milestones https://www.biospace.com/press-releases/arch-biopartners-receives-central-irb-approval-to-support-u-s-sites-in-phase-ii-cardiac-surgery-associated-acute-kidney-injury-trial-of-lsalt-peptide Mon, 31 Aug 2026 13:17:39 GMT https://www.biospace.com/press-releases/arch-biopartners-receives-central-irb-approval-to-support-u-s-sites-in-phase-ii-cardiac-surgery-associated-acute-kidney-injury-trial-of-lsalt-peptide https://www.biospace.com/press-releases/bayer-to-present-new-phase-iii-data-from-its-cardiovascular-kidney-and-stroke-clinical-trial-programs-at-esc-2026 Thu, 20 Aug 2026 13:33:58 GMT https://www.biospace.com/press-releases/bayer-to-present-new-phase-iii-data-from-its-cardiovascular-kidney-and-stroke-clinical-trial-programs-at-esc-2026 https://www.biospace.com/press-releases/arch-biopartners-to-expand-phase-ii-cardiac-surgery-associated-acute-kidney-injury-trial-to-the-united-states Tue, 11 Aug 2026 12:56:01 GMT https://www.biospace.com/press-releases/arch-biopartners-to-expand-phase-ii-cardiac-surgery-associated-acute-kidney-injury-trial-to-the-united-states https://www.biospace.com/press-releases/mironid-raises-46-million-in-series-b-financing-to-advance-clinical-development-of-its-treatment-for-rare-kidney-disease Wed, 05 Aug 2026 10:22:56 GMT https://www.biospace.com/press-releases/mironid-raises-46-million-in-series-b-financing-to-advance-clinical-development-of-its-treatment-for-rare-kidney-disease https://www.biospace.com/press-releases/akebia-therapeutics-announces-initiation-of-a-phase-2-basket-trial-to-study-ebribafusp-a-next-generation-complement-inhibitor-in-rare-kidney-diseases Mon, 03 Aug 2026 14:11:30 GMT https://www.biospace.com/press-releases/akebia-therapeutics-announces-initiation-of-a-phase-2-basket-trial-to-study-ebribafusp-a-next-generation-complement-inhibitor-in-rare-kidney-diseases https://www.biospace.com/press-releases/mannkind-announces-fda-approval-of-furoscix-readyflow-the-first-and-only-autoinjector-delivering-iv-equivalent-diuretic-therapy-for-the-treatment-of-edema-in-adults-with-heart-failure-or-chronic-kidney-disease Fri, 24 Jul 2026 13:25:30 GMT https://www.biospace.com/press-releases/mannkind-announces-fda-approval-of-furoscix-readyflow-the-first-and-only-autoinjector-delivering-iv-equivalent-diuretic-therapy-for-the-treatment-of-edema-in-adults-with-heart-failure-or-chronic-kidney-disease https://www.biospace.com/press-releases/rege-nephro-secures-approximately-us-10-6-million-to-advance-rn-014-toward-commercialization Tue, 21 Jul 2026 11:20:16 GMT https://www.biospace.com/press-releases/rege-nephro-secures-approximately-us-10-6-million-to-advance-rn-014-toward-commercialization https://www.biospace.com/press-releases/arch-biopartners-engages-private-laboratory-to-accelerate-il-32-chronic-kidney-disease-program Fri, 17 Jul 2026 13:12:44 GMT https://www.biospace.com/press-releases/arch-biopartners-engages-private-laboratory-to-accelerate-il-32-chronic-kidney-disease-program https://www.biospace.com/press-releases/dimerix-expands-pipeline-with-acquisition-of-phase-2-ready-asset-for-acute-kidney-injury Fri, 17 Jul 2026 13:10:28 GMT https://www.biospace.com/press-releases/dimerix-expands-pipeline-with-acquisition-of-phase-2-ready-asset-for-acute-kidney-injury https://www.biospace.com/press-releases/mission-therapeutics-strikes-deal-worth-up-to-292-million-for-dimerix-ltd-to-develop-acute-kidney-injury-asset-mtx652-sharpens-focus-on-its-cns-pipeline Fri, 17 Jul 2026 13:04:45 GMT https://www.biospace.com/press-releases/mission-therapeutics-strikes-deal-worth-up-to-292-million-for-dimerix-ltd-to-develop-acute-kidney-injury-asset-mtx652-sharpens-focus-on-its-cns-pipeline https://www.biospace.com/press-releases/dr-marc-hurlbert-begins-tenure-as-chief-executive-officer-of-the-national-kidney-foundation Wed, 01 Jul 2026 14:13:35 GMT https://www.biospace.com/press-releases/dr-marc-hurlbert-begins-tenure-as-chief-executive-officer-of-the-national-kidney-foundation